<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D657B59F-F040-46B5-A35B-D457C06CE596"><gtr:id>D657B59F-F040-46B5-A35B-D457C06CE596</gtr:id><gtr:name>Becton, Dickinson and Company (BD)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C705F4C9-3E9D-4C2A-90B0-49C636E962EE"><gtr:id>C705F4C9-3E9D-4C2A-90B0-49C636E962EE</gtr:id><gtr:name>Barts Health NHS Trust</gtr:name><gtr:address><gtr:line1>9 Prescot Street
Aldgate</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>E1 8PR</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3DBCEE86-6873-4669-9B35-B4EEEAE13F52"><gtr:id>3DBCEE86-6873-4669-9B35-B4EEEAE13F52</gtr:id><gtr:name>Royal Liverpool University NHS Hospitals</gtr:name><gtr:address><gtr:line1>Prescot Street</gtr:line1><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L7 8XP</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F3EF5FCD-A744-49AF-8A77-AFAC5FA8337F"><gtr:id>F3EF5FCD-A744-49AF-8A77-AFAC5FA8337F</gtr:id><gtr:name>Celgene</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3DF2F8DD-33A5-44A1-81D7-347A6C2FBDC8"><gtr:id>3DF2F8DD-33A5-44A1-81D7-347A6C2FBDC8</gtr:id><gtr:name>Stanford University</gtr:name><gtr:address><gtr:line1>450 Serra Mall</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3545CDC8-076D-4BD8-B370-8E558F9D46EE"><gtr:id>3545CDC8-076D-4BD8-B370-8E558F9D46EE</gtr:id><gtr:name>Leeds Teaching Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Beckett Street</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS9 7TF</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/274F2FB0-27BB-4991-A894-796A2AE916E3"><gtr:id>274F2FB0-27BB-4991-A894-796A2AE916E3</gtr:id><gtr:name>The Christie NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Wilmslow Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M20 4BX</gtr:postCode><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DD1F1403-9928-4563-8E48-326ACF87C706"><gtr:id>DD1F1403-9928-4563-8E48-326ACF87C706</gtr:id><gtr:name>University Hospital of Wales</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Weatherall Inst of Molecular Medicine</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D657B59F-F040-46B5-A35B-D457C06CE596"><gtr:id>D657B59F-F040-46B5-A35B-D457C06CE596</gtr:id><gtr:name>Becton, Dickinson and Company (BD)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C705F4C9-3E9D-4C2A-90B0-49C636E962EE"><gtr:id>C705F4C9-3E9D-4C2A-90B0-49C636E962EE</gtr:id><gtr:name>Barts Health NHS Trust</gtr:name><gtr:address><gtr:line1>9 Prescot Street
Aldgate</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>E1 8PR</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3DBCEE86-6873-4669-9B35-B4EEEAE13F52"><gtr:id>3DBCEE86-6873-4669-9B35-B4EEEAE13F52</gtr:id><gtr:name>Royal Liverpool University NHS Hospitals</gtr:name><gtr:address><gtr:line1>Prescot Street</gtr:line1><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L7 8XP</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F3EF5FCD-A744-49AF-8A77-AFAC5FA8337F"><gtr:id>F3EF5FCD-A744-49AF-8A77-AFAC5FA8337F</gtr:id><gtr:name>Celgene</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3DF2F8DD-33A5-44A1-81D7-347A6C2FBDC8"><gtr:id>3DF2F8DD-33A5-44A1-81D7-347A6C2FBDC8</gtr:id><gtr:name>Stanford University</gtr:name><gtr:address><gtr:line1>450 Serra Mall</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3545CDC8-076D-4BD8-B370-8E558F9D46EE"><gtr:id>3545CDC8-076D-4BD8-B370-8E558F9D46EE</gtr:id><gtr:name>Leeds Teaching Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Beckett Street</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS9 7TF</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/274F2FB0-27BB-4991-A894-796A2AE916E3"><gtr:id>274F2FB0-27BB-4991-A894-796A2AE916E3</gtr:id><gtr:name>The Christie NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Wilmslow Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M20 4BX</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DD1F1403-9928-4563-8E48-326ACF87C706"><gtr:id>DD1F1403-9928-4563-8E48-326ACF87C706</gtr:id><gtr:name>University Hospital of Wales</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7C77CA31-E4B1-49B0-B014-0CE3E7BA17D0"><gtr:id>7C77CA31-E4B1-49B0-B014-0CE3E7BA17D0</gtr:id><gtr:firstName>Paresh</gtr:firstName><gtr:surname>Vyas</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1000729"><gtr:id>C7E290C0-B2BD-4ACF-8331-39E0195E9126</gtr:id><gtr:title>Development ofTherapeutic Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1000729</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Acute myeloid leukemia (AML) is an aggressive malignancy of the bone marrow with strong
evidence for the critical involvement of self-renewing leukemia stem cells (LSC) in disease
pathogenesis. We and others have proposed that AML LSC must be eradicated to achieve cure,
yet these cells are resistant to standard chemotherapy and radiation treatments. Our approach
to the development of novel AML therapeutics is to produce therapeutic antibodies directed
against cell surface antigens preferentially expressed on clinically relevant AML stem cells. We
identified and validated LSC-preferential expression of CD47, CD96, CD97, and TIM3 using
antigen-specific monoclonal antibodies. CD47 functions as a ?don?t eat me? signal by binding to
SIRP.. on phagocytic cells and delivering a dominant inhibitory signal. We determined that a
blocking anti-CD47 monoclonal antibody targets and depletes LSC in a mouse
xenotransplantation model by enabling their in vivo phagocytosis and elimination. We propose
to develop a clinical grade therapeutic antibody through the following aims:
(1): To define the surface marker expression of clinically relevant AML LSC in serial bone
marrow samples from patients enrolled in the UK NCRI AML 16 and 17 trials
(2): To develop humanized blocking monoclonal antibodies directed against human CD47
(3): To develop humanized recombinant monoclonal and/or bi-specific antibodies targeting
CD47 in combination with other AML LSC-specific proteins
(4): To develop a GMP grade antibody from the best candidate, including pre-clinical
toxicokinetic studies and large-scale production, and submit an IND filing with the FDA/MHRA</gtr:technicalSummary><gtr:fund><gtr:end>2016-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1992332</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration on therapy of high risk MDS and AML.</gtr:description><gtr:id>A96B86A9-D657-4F30-B4A4-3388A6C4B0CD</gtr:id><gtr:impact>Quek L*, Ferguson P*, Metzner M, Ahmed I, Kennedy A, Garnett C, Jeffries S, Walter C, Piechocki K, Timbs A, Danby R, Raghavan M, Peniket A, Griffiths M, Bacon A, Ward J, Wheatley K, Vyas P*, Craddock C*. Mutational Analysis of Disease Relapse in Patients Allografted for Acute Myeloid Leukemia

Khan N, Hills RK, Knapper S, Steadman L, Qureshi U, Rector JL, Bradbury C, Russell NH, Vyas P, Burnett AK, Grimwade D, Hole PS, Freeman SD. Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia PLoS One. 2016 Sep 26;11(9):e0163291. PMID: 27669008

Craddock C, Jilani NY, Siddique S, Yap C, Khan JN, Nagra S, Ward J, Ferguson P, Hazlewood P, Buka R, Vyas P, Goodyear OC, Tholouli E, Crawley C, Russell N, Byrne J, Malladi R, Snowden JA, Dennis M. Tolerability and clinical activity of post-transplant Azacitidine in patients allografted for Acute Myeloid Leukaemia treated on the RICAZA trial. Biol Blood Marrow Transplant. Sep 9. pii: S1083-8791(15)00609-6. doi: 10.1016/j.bbmt.2015.09.004. (2015).

Bradbury C, Houlton AE, Akiki S, Gregg R, Rindl M, Khan J, Ward J, Khan N, Griffiths M, Nagra S, Hills R, Burnett A, Russell N, Vyas P, Grimwade D, Craddock C, Freeman SD. Prognostic value of monitoring a candidate immunophenotypic leukemic stem/progenitor cell population in patients allografted for acute myeloid leukemia. Leukemia. 29 p988-91. (2014) PMID:25425198.

Craddock C, Goardon N, Quek L, Freeman S, Siddique S, Raghavan M, Schuh A, Grimwade D, Virgo P, Hills R, McSkeane T, Arrazi J, Gilkes A, Knapper, Adam Ivey, Brookes C, Miles O, Davies B, Chaudhury S, Pollard T, Price A, Atzberger A, Wall K, Kaur H, Griffiths M, Cavenagh, Majeti R, Weissman I, Burnett A, Vyas P. Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukaemia 27:p1028-36 (2013). 

Goodyear O, Dennis M, Loke J, Jilani N, Siddique S, Ryan G, J Nunnick, Khanum R, Raghavan M, Cook M, Snowden J, Griffiths M, Russell N, Yin J, Crawley C, Cook G, Vyas P, Moss P, Malladi R, Craddock C. Azacitidine Induces Expansion of Regulatory T Cells and Induces a Tumor Antigen Specific Response after Allogeneic Stem Cell Transplantation in patients with AML. Blood. 119: p3361-9. (2012).

Co-administration of Vorinostat Does Not Improve Outcome of Patients with of Acute Myeloid Leukemia Treated with Azacitidine

Charles Craddock, MD, PhD1, Aimee E Houlton, BSc, MSc2*, Lynn Swun Quek, DPhil, FRCPath, Paul Ferguson, MBChB MRCP PhD3; Emma Gbandi, Corran Roberts (affiliation and degree needed), *, Marlen Metzner, Alison Kennedy, Manoj Raghavan4*, Sandeep Nagra1*, Louise Dudley, BSc, MRes5*, DPhil, MBBS6*, Sharon Love, Jamie D. Cavenagh7, Michael Dennis, FRCPath8*, Mary Frances McMullin, MD9, Srinivas P Pillai10*, Richard Kelly, BSc, MD11*, Shamyla Siddique12*, Keith Wheatley, DPhil13 and Paresh Vyas, BM, DPhil, FRCP, FRCPath14

Submitted

Grants: 2015-2018 Therapy Acceleration Programme &amp;pound;92 778. 
Leukaemia Lymphoma Research Funded Trial Infrastructure Programme</gtr:impact><gtr:outcomeId>56d4624608b956.62272713-1</gtr:outcomeId><gtr:partnerContribution>Clinical Trial Lead</gtr:partnerContribution><gtr:piContribution>Understanding AML Leukaemic stem cell biology. Assessment of Leukaemic stem cells (LSC) as a marker of minimal residual disease. This is evaluated using samples from clinical trials.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leeds Teaching Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Clinical Haematology</gtr:department><gtr:description>Clinical Trial of Anti-CD47</gtr:description><gtr:id>07E2A059-2412-4AC4-84FB-B984EB1B62F6</gtr:id><gtr:impact>1. We successfully secured MRC (2015 and 2009 ) and Bloodwise (2015) funding for this trial. 

2. The drug is safe we will aim to perform a Phase II trial in 2017 in AML.</gtr:impact><gtr:outcomeId>otB4e8B6Y2B-4</gtr:outcomeId><gtr:partnerContribution>Stanford University have made the therapeutic. There are 5 UK hospitals site that will run the trial. 
A company, CD47 Inc, has spun out of Stanford University and is now the sponsor of this trial. Oxford University has a revenue sharing agreement with Stanford University.</gtr:partnerContribution><gtr:piContribution>I have written the Phase I clinical trial Protocol for use of Anti-CD47 in a first in class first in man clinical trial. I will coordinate CTA application and NRES application. My lab will perform exploratory PD biomarker analysis. I will be CI of the trial.

Phase I trial to started 2015.

Phase II trials to start 2017.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Oncology</gtr:department><gtr:description>Clinical Trial of Anti-CD47</gtr:description><gtr:id>A9DBAAC0-4824-4226-AA48-5FBBDD876AF2</gtr:id><gtr:impact>1. We successfully secured MRC (2015 and 2009 ) and Bloodwise (2015) funding for this trial. 

2. The drug is safe we will aim to perform a Phase II trial in 2017 in AML.</gtr:impact><gtr:outcomeId>otB4e8B6Y2B-2</gtr:outcomeId><gtr:partnerContribution>Stanford University have made the therapeutic. There are 5 UK hospitals site that will run the trial. 
A company, CD47 Inc, has spun out of Stanford University and is now the sponsor of this trial. Oxford University has a revenue sharing agreement with Stanford University.</gtr:partnerContribution><gtr:piContribution>I have written the Phase I clinical trial Protocol for use of Anti-CD47 in a first in class first in man clinical trial. I will coordinate CTA application and NRES application. My lab will perform exploratory PD biomarker analysis. I will be CI of the trial.

Phase I trial to started 2015.

Phase II trials to start 2017.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Stanford University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Stem Cell Institute Stanford</gtr:department><gtr:description>Clinical Trial of Anti-CD47</gtr:description><gtr:id>B67079E8-4639-4667-8379-CEA790808A1C</gtr:id><gtr:impact>1. We successfully secured MRC (2015 and 2009 ) and Bloodwise (2015) funding for this trial. 

2. The drug is safe we will aim to perform a Phase II trial in 2017 in AML.</gtr:impact><gtr:outcomeId>otB4e8B6Y2B-1</gtr:outcomeId><gtr:partnerContribution>Stanford University have made the therapeutic. There are 5 UK hospitals site that will run the trial. 
A company, CD47 Inc, has spun out of Stanford University and is now the sponsor of this trial. Oxford University has a revenue sharing agreement with Stanford University.</gtr:partnerContribution><gtr:piContribution>I have written the Phase I clinical trial Protocol for use of Anti-CD47 in a first in class first in man clinical trial. I will coordinate CTA application and NRES application. My lab will perform exploratory PD biomarker analysis. I will be CI of the trial.

Phase I trial to started 2015.

Phase II trials to start 2017.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Haematology</gtr:department><gtr:description>Development of novel therapeutic anti-leuakemia stem cell antibodies</gtr:description><gtr:id>89DD3CC5-D5F0-4CCB-BBFE-12F6AA5C325D</gtr:id><gtr:impact>Grants 2009 &amp;pound;2.2 M MRC Disease Team Award Publications (PubMed ID numbers below): 19664981 19546437 19644143</gtr:impact><gtr:outcomeId>B7E2966F68D-3</gtr:outcomeId><gtr:partnerContribution>It has provided access to novel technologies and unpublished dataAccess to novel therapies. Access to patient samples. Access to laboratory collaborations. Acquisition of biological samples and clinical data. Acquisition of biological samples and clinical data</gtr:partnerContribution><gtr:piContribution>We lead the UK component of this transatlantic collaboration. The basic science and translational studies are driven from Oxford.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>WGS and additional biologic studies of haem tumours.</gtr:description><gtr:id>6217BC85-AFB5-4490-9C29-373A4CB38997</gtr:id><gtr:impact>Zabkiewicz J, Gilmour M, Hills R, Vyas P, Bone E, Davidson A, Burnett A, Knapper S. The targeted histone deacetylas inhibitor tefinostst (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias. Oncotarget. 2016 Feb 25. doi: 10.18632/oncotarget.7692. PMID: 26934551

Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, Patel Y, Bhudia N, Farah H, Mason J, Wall K, Akiki S, Griffiths, M, Solomon E, McCaughan F, Linch D, Gale R, Vyas P, Freeman S, Russell N, Burnett, A and Grimwade D, for the UK National Cancer Research Institute AML Working Group. Assessment of Minimal Residual Disease in Standard Risk AML. NEJM 374 p422-33. (2016). PMID: 26789727</gtr:impact><gtr:outcomeId>56d46335697c37.53806607-1</gtr:outcomeId><gtr:partnerContribution>University of Oxford - Lead of AML GECIP (Vyas) and overall haem GECIP (Schuh)
University of Cardiff - Sponsor of Trial</gtr:partnerContribution><gtr:piContribution>Design of the program of WGS and integrated multi-&amp;quot;omic&amp;quot; reseatch program on AML UK NCRI AML clinical trial samples to define clonal structures in human AML and how they change in response to therapy. To determine molecular and cellular mechanisms of therapy resistance.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Stanford University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Stem Cell Institute Stanford</gtr:department><gtr:description>LSC surface antigen detection and generation of antibodies for diagnostic and therapuetic purposes</gtr:description><gtr:id>D7020BC7-386B-45DE-BBBB-08B6BA5FB7E5</gtr:id><gtr:impact>Shared new reagents.
We have a Patent applied for.
We have MTAs with becton Dickinson, Stanford University, University of Birmingham.
Joint collaboration with Becton Dickinson and Stanford University.</gtr:impact><gtr:outcomeId>G92Jz3To1Wx-1</gtr:outcomeId><gtr:partnerContribution>Sharing of reagents.

Developing new antibodies for therapeutic and diagnostic purposes.</gtr:partnerContribution><gtr:piContribution>We have identified candidate antigens on leukaemic stem cells (LSC) in Acute Myeloid Leukaemia (AML).
We test the utility of antibodies to these antigens to detect AML LSC.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Liverpool University Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Haematology</gtr:department><gtr:description>Clinical Trial of Anti-CD47</gtr:description><gtr:id>045A1562-3550-4D9E-8530-0093B3DBB31A</gtr:id><gtr:impact>1. We successfully secured MRC (2015 and 2009 ) and Bloodwise (2015) funding for this trial. 

2. The drug is safe we will aim to perform a Phase II trial in 2017 in AML.</gtr:impact><gtr:outcomeId>otB4e8B6Y2B-5</gtr:outcomeId><gtr:partnerContribution>Stanford University have made the therapeutic. There are 5 UK hospitals site that will run the trial. 
A company, CD47 Inc, has spun out of Stanford University and is now the sponsor of this trial. Oxford University has a revenue sharing agreement with Stanford University.</gtr:partnerContribution><gtr:piContribution>I have written the Phase I clinical trial Protocol for use of Anti-CD47 in a first in class first in man clinical trial. I will coordinate CTA application and NRES application. My lab will perform exploratory PD biomarker analysis. I will be CI of the trial.

Phase I trial to started 2015.

Phase II trials to start 2017.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Christie NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Haematology and Transplant Unit</gtr:department><gtr:description>Clinical Trial of Anti-CD47</gtr:description><gtr:id>E0B46AD0-EC1F-49D1-A728-B71E706D67C8</gtr:id><gtr:impact>1. We successfully secured MRC (2015 and 2009 ) and Bloodwise (2015) funding for this trial. 

2. The drug is safe we will aim to perform a Phase II trial in 2017 in AML.</gtr:impact><gtr:outcomeId>otB4e8B6Y2B-7</gtr:outcomeId><gtr:partnerContribution>Stanford University have made the therapeutic. There are 5 UK hospitals site that will run the trial. 
A company, CD47 Inc, has spun out of Stanford University and is now the sponsor of this trial. Oxford University has a revenue sharing agreement with Stanford University.</gtr:partnerContribution><gtr:piContribution>I have written the Phase I clinical trial Protocol for use of Anti-CD47 in a first in class first in man clinical trial. I will coordinate CTA application and NRES application. My lab will perform exploratory PD biomarker analysis. I will be CI of the trial.

Phase I trial to started 2015.

Phase II trials to start 2017.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Birmingham NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Queen Elizabeth Medical Centre, Birmingham</gtr:department><gtr:description>Development of novel therapeutic anti-leuakemia stem cell antibodies</gtr:description><gtr:id>90DAA53E-826E-4819-98DC-0694CA806448</gtr:id><gtr:impact>Grants 2009 &amp;pound;2.2 M MRC Disease Team Award Publications (PubMed ID numbers below): 19664981 19546437 19644143</gtr:impact><gtr:outcomeId>B7E2966F68D-2</gtr:outcomeId><gtr:partnerContribution>It has provided access to novel technologies and unpublished dataAccess to novel therapies. Access to patient samples. Access to laboratory collaborations. Acquisition of biological samples and clinical data. Acquisition of biological samples and clinical data</gtr:partnerContribution><gtr:piContribution>We lead the UK component of this transatlantic collaboration. The basic science and translational studies are driven from Oxford.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Barts Health NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Haematology</gtr:department><gtr:description>Development of novel therapeutic anti-leuakemia stem cell antibodies</gtr:description><gtr:id>D8E537F5-640E-4A13-B34A-C676CD2D6ECF</gtr:id><gtr:impact>Grants 2009 &amp;pound;2.2 M MRC Disease Team Award Publications (PubMed ID numbers below): 19664981 19546437 19644143</gtr:impact><gtr:outcomeId>B7E2966F68D-4</gtr:outcomeId><gtr:partnerContribution>It has provided access to novel technologies and unpublished dataAccess to novel therapies. Access to patient samples. Access to laboratory collaborations. Acquisition of biological samples and clinical data. Acquisition of biological samples and clinical data</gtr:partnerContribution><gtr:piContribution>We lead the UK component of this transatlantic collaboration. The basic science and translational studies are driven from Oxford.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Celgene</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Epigenetics of Acute Myeloid Leukaemia</gtr:description><gtr:id>D8479F9E-D4D5-44D7-BED4-D87BDFF9461D</gtr:id><gtr:impact>Multidisciplinary collaboration. Involving medicinal chemists and biologists.</gtr:impact><gtr:outcomeId>DcxxCt87wvu-1</gtr:outcomeId><gtr:partnerContribution>Access to demethylation agents for experiments</gtr:partnerContribution><gtr:piContribution>Study of epigenetic changes in Leukaemic stem cells in Acute Myeloid Leukaemia</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Haematology</gtr:department><gtr:description>Clinical Trial of Anti-CD47</gtr:description><gtr:id>F9F7FB9B-9115-4DD4-A0A3-2A154082DC01</gtr:id><gtr:impact>1. We successfully secured MRC (2015 and 2009 ) and Bloodwise (2015) funding for this trial. 

2. The drug is safe we will aim to perform a Phase II trial in 2017 in AML.</gtr:impact><gtr:outcomeId>otB4e8B6Y2B-3</gtr:outcomeId><gtr:partnerContribution>Stanford University have made the therapeutic. There are 5 UK hospitals site that will run the trial. 
A company, CD47 Inc, has spun out of Stanford University and is now the sponsor of this trial. Oxford University has a revenue sharing agreement with Stanford University.</gtr:partnerContribution><gtr:piContribution>I have written the Phase I clinical trial Protocol for use of Anti-CD47 in a first in class first in man clinical trial. I will coordinate CTA application and NRES application. My lab will perform exploratory PD biomarker analysis. I will be CI of the trial.

Phase I trial to started 2015.

Phase II trials to start 2017.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>WGS and additional biologic studies of haem tumours.</gtr:description><gtr:id>EA749FDA-5090-4AD5-AA31-E78B904E61FE</gtr:id><gtr:impact>Zabkiewicz J, Gilmour M, Hills R, Vyas P, Bone E, Davidson A, Burnett A, Knapper S. The targeted histone deacetylas inhibitor tefinostst (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias. Oncotarget. 2016 Feb 25. doi: 10.18632/oncotarget.7692. PMID: 26934551

Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, Patel Y, Bhudia N, Farah H, Mason J, Wall K, Akiki S, Griffiths, M, Solomon E, McCaughan F, Linch D, Gale R, Vyas P, Freeman S, Russell N, Burnett, A and Grimwade D, for the UK National Cancer Research Institute AML Working Group. Assessment of Minimal Residual Disease in Standard Risk AML. NEJM 374 p422-33. (2016). PMID: 26789727</gtr:impact><gtr:outcomeId>56d46335697c37.53806607-2</gtr:outcomeId><gtr:partnerContribution>University of Oxford - Lead of AML GECIP (Vyas) and overall haem GECIP (Schuh)
University of Cardiff - Sponsor of Trial</gtr:partnerContribution><gtr:piContribution>Design of the program of WGS and integrated multi-&amp;quot;omic&amp;quot; reseatch program on AML UK NCRI AML clinical trial samples to define clonal structures in human AML and how they change in response to therapy. To determine molecular and cellular mechanisms of therapy resistance.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCL Cancer Institute</gtr:department><gtr:description>Investigation of leukaemic Stem Cell biology in Childhood AML</gtr:description><gtr:id>7754D0B3-410A-4BBD-9665-E7BBFF696BDC</gtr:id><gtr:impact>No outputs yet.</gtr:impact><gtr:outcomeId>qED31tpBD9A-1</gtr:outcomeId><gtr:partnerContribution>They have studied gene expression programmes ad are developing vectors to introduce nucleic acid sequences into LSCs.</gtr:partnerContribution><gtr:piContribution>We have fractionated LSC from childhood AML samples. We are studying the molecular and genetic heterogeneity.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Stanford University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Development of novel therapeutic anti-leuakemia stem cell antibodies</gtr:description><gtr:id>03D54CEF-5C72-4E11-A1F3-ACF25BC369C6</gtr:id><gtr:impact>Grants 2009 &amp;pound;2.2 M MRC Disease Team Award Publications (PubMed ID numbers below): 19664981 19546437 19644143</gtr:impact><gtr:outcomeId>B7E2966F68D-1</gtr:outcomeId><gtr:partnerContribution>It has provided access to novel technologies and unpublished dataAccess to novel therapies. Access to patient samples. Access to laboratory collaborations. Acquisition of biological samples and clinical data. Acquisition of biological samples and clinical data</gtr:partnerContribution><gtr:piContribution>We lead the UK component of this transatlantic collaboration. The basic science and translational studies are driven from Oxford.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Becton, Dickinson and Company (BD)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Collaboration with the company Becton Dickinson</gtr:description><gtr:id>7D44A8D0-8CBD-4A2D-9DD8-1ACB9D4EEC15</gtr:id><gtr:impact>There is a patent filed. Becton Dickinson has paid for the option to have first rights to licence. 

Data is not yet mature for publication. This is multidisciplinary. It involves clinical colleagues, industry, and the laboratories in Oxford and Stanford.</gtr:impact><gtr:outcomeId>C3KHzD8XsmU-1</gtr:outcomeId><gtr:partnerContribution>The company has developed a new series of monoclonal antibody reagents for FACS-based detection of leukaemic stem cells (LSC) based on our data and data in the field.

We are evaluating the commercial possibility of using a FACS-based LSC detection panel to quantitate minimal residual disease (MRD) in patients on treatment for AML.</gtr:partnerContribution><gtr:piContribution>We identified novel LSC surface antigens. We designed the panel. Both of these were done in collaboration with our colleagues in Stanford.

We have tested the panel.

We are obtaining data on patients undergoing treatment in the UK AML trials.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital of Wales</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Haematology</gtr:department><gtr:description>Clinical Trial of Anti-CD47</gtr:description><gtr:id>28AEB5C4-1B61-467A-8A68-2246BABB6B12</gtr:id><gtr:impact>1. We successfully secured MRC (2015 and 2009 ) and Bloodwise (2015) funding for this trial. 

2. The drug is safe we will aim to perform a Phase II trial in 2017 in AML.</gtr:impact><gtr:outcomeId>otB4e8B6Y2B-6</gtr:outcomeId><gtr:partnerContribution>Stanford University have made the therapeutic. There are 5 UK hospitals site that will run the trial. 
A company, CD47 Inc, has spun out of Stanford University and is now the sponsor of this trial. Oxford University has a revenue sharing agreement with Stanford University.</gtr:partnerContribution><gtr:piContribution>I have written the Phase I clinical trial Protocol for use of Anti-CD47 in a first in class first in man clinical trial. I will coordinate CTA application and NRES application. My lab will perform exploratory PD biomarker analysis. I will be CI of the trial.

Phase I trial to started 2015.

Phase II trials to start 2017.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Stanford University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Stem Cell Institute Stanford</gtr:department><gtr:description>Collaboration with the company Becton Dickinson</gtr:description><gtr:id>F5639913-DD10-440C-B327-D906190F65E4</gtr:id><gtr:impact>There is a patent filed. Becton Dickinson has paid for the option to have first rights to licence. 

Data is not yet mature for publication. This is multidisciplinary. It involves clinical colleagues, industry, and the laboratories in Oxford and Stanford.</gtr:impact><gtr:outcomeId>C3KHzD8XsmU-2</gtr:outcomeId><gtr:partnerContribution>The company has developed a new series of monoclonal antibody reagents for FACS-based detection of leukaemic stem cells (LSC) based on our data and data in the field.

We are evaluating the commercial possibility of using a FACS-based LSC detection panel to quantitate minimal residual disease (MRD) in patients on treatment for AML.</gtr:partnerContribution><gtr:piContribution>We identified novel LSC surface antigens. We designed the panel. Both of these were done in collaboration with our colleagues in Stanford.

We have tested the panel.

We are obtaining data on patients undergoing treatment in the UK AML trials.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Video for patients</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5D6C6CB9-18FD-4FA0-B827-88C758FF3A2B</gtr:id><gtr:impact>Made a video for patients to explain the symptoms and signs of Myelodysplasia and some of the treatments available

Increased patient awareness
Led in part to the petition to Parliament to reclassify MDS as a cancer</gtr:impact><gtr:outcomeId>X78kmiXXMLA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science Week</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E57AB7CE-372B-44CC-931F-5E1F293D35DD</gtr:id><gtr:impact>Oxford Science Week is held annually to an audience of scientists and the general public.

Good feedback from schools</gtr:impact><gtr:outcomeId>67D8B48106B</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interview with television</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6412FBEB-8F26-43E1-8BBF-4FA738F3A6A7</gtr:id><gtr:impact>I gave a 3 minute interview screened on ITV Central New bulletin at 6 pm and 10 pm.

Public interest in drug trials in leukaemia</gtr:impact><gtr:outcomeId>Gt2TRGoU5rD</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lynn Quek - UK MDS Forum</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>2C4770E9-5C67-41FB-BD4E-C6CF78BB86AC</gtr:id><gtr:impact>Talk on Differentiation Block in AML at the UK MDS Forum.</gtr:impact><gtr:outcomeId>58c00f28398e81.04092762</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Student Presentations</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>9A2E6563-E12C-4CA4-A3A4-437D738986E7</gtr:id><gtr:impact>Final year students present their work to the members of the Weatherall Institute of Molecular Medicine. This presentation day is held annually.

Improved student training.</gtr:impact><gtr:outcomeId>F30E22D719D</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lynn Quek  - Celgene Platform for the Exchange of Expertise and Research</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>1EE8F0EC-887E-4CE5-A919-8D94B229A4F0</gtr:id><gtr:impact>Talk about Translational Research in Haematology at the Celgene Platform the Exchange of Expertise and Research</gtr:impact><gtr:outcomeId>58c01020b50e02.87389803</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Open Day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>256255A5-3854-4335-B2F2-A18632864198</gtr:id><gtr:impact>88 members of the general public attended a series of short presentations and Question and Answer session on what benefit research plays in advancing health.

Positive feedback and a request for annual repeat of the session</gtr:impact><gtr:outcomeId>p7pT6cTwu7w</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Oxford Radio Interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>21F3B58D-B5A0-4841-AE11-5BCABED45BDA</gtr:id><gtr:impact>Discussion on public access to new drugs made possible by research

Increased local awareness of clinical trials funded by academic funded research</gtr:impact><gtr:outcomeId>jkKJFbtrpKn</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>440000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Programme Grant</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>C7F53618-A417-49E4-B1A5-D554B1B11FFA</gtr:id><gtr:outcomeId>hT2syNvbftE0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>780000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Oxford BRC - Joint Application</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>F702B686-E2E1-462D-A2E4-90B4EADBAC14</gtr:id><gtr:outcomeId>EB395yXaYqA</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>19845</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Understanding heterogeneity of treatment response in 'standard' risk acute myeloid leukaemia</gtr:description><gtr:end>2018-10-02</gtr:end><gtr:fundingOrg>Bloodwise</gtr:fundingOrg><gtr:id>7C917116-97FD-4F85-A235-B604990D358F</gtr:id><gtr:outcomeId>58763862d71061.28096815</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>308470</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>LLR - Leukaemia &amp;amp; Lymphoma Research. CTAP (Clinical Trial)</gtr:description><gtr:end>2018-02-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>12BCB902-E583-4263-AC30-265D93E5FFA4</gtr:id><gtr:outcomeId>56cd745825cbc3.34929267</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2009 Disease Team Award</gtr:description><gtr:end>2014-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>90646465-03B1-4259-8F89-57EE14C1029D</gtr:id><gtr:outcomeId>55756B3EA280</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>520000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Molecular Haematology Unit Award</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>19647BED-4B39-4511-8D3D-9A9E0AEBA497</gtr:id><gtr:outcomeId>gtvjc4DAy2Y</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>174000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Celgene PhD Studentship</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Celgene</gtr:fundingOrg><gtr:id>0C6C2BB9-9271-4E9D-9636-F414EF7AD05D</gtr:id><gtr:outcomeId>F10F7B4B6040</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>233726</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinical Training Fellowship</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>00A7F711-324B-4ED2-8AD7-39D80272B73D</gtr:id><gtr:outcomeId>545fdc960bc726.29148474</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre</gtr:department><gtr:description>Haematology and Stem Cell Theme Oxford Biomedical Research Centre (NIHR)</gtr:description><gtr:end>2022-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>4C626675-9A64-4920-9875-52AE9916EF9E</gtr:id><gtr:outcomeId>58bfd91beaf544.69148880</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Immunophenotypic detection of AML LSC</gtr:description><gtr:grantRef>G1000729</gtr:grantRef><gtr:id>5A88F39F-C12F-471E-8413-DEBF7521D115</gtr:id><gtr:impact>We are developing a commercial product with the company BD</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>WSjAyBYMFZ3</gtr:outcomeId><gtr:patentId>WO2012085574</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Immunophenotypic detection of AML LSC</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>LSC detection is now part of the UK AML trial laboratory studies fro MRD detection</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D84FDAFD-E563-428F-B1F1-F2359BF52B80</gtr:id><gtr:impact>The change if validated over the next 2-3 years will transform the detection of residual leukaemia post therapy and have implication for the necessity of additional post remission therapy. There will be implications for other cancers as a whole.</gtr:impact><gtr:outcomeId>rrnG4YjcDkr</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Monitoring of Acute Myeloid Leukaemia stem cells (LSC) in patients receiving treatment</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5D99BF05-35E5-499A-A064-C6B4E641FF59</gtr:id><gtr:impact>Our protocol of monitoring AML LSC has changed national practice. This is now routine for UK AML trials that recruit 95% of all UK AML patients under 60 years old.</gtr:impact><gtr:outcomeId>D9156B99097</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>IMPACT - Transplantation Trials Practice</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>02AD42FD-5002-4326-99DE-27C69CABBCCA</gtr:id><gtr:outcomeId>58c00b4af33c92.06412858</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>UK Stem Cell Strategic Forum</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B69AA5C1-76BE-44D9-A62C-FBF9E5BCD9B0</gtr:id><gtr:impact>Provided evidence on how to structure research and development using blood stem cells for a Report commissioned by DoH and involving NHSBT, Anthony Nolan Trust, DoH, Lead clinicians in Bone Marrow transplantation and members of the Devolved Administrations.</gtr:impact><gtr:outcomeId>tfHTGM3BPTK</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Geoff Thomas Foundation</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FF4BC690-175A-4EA6-9246-DB7F05531E27</gtr:id><gtr:impact>Prof Vyas has advised the Geoff Thomas Foundation (GTF) (http://www.geoffthomasfoundation.org/site/index.php) - a Football Association (FA) charity raising money and awareness to fight blood cancers. Dr Vyas has attended meetings with parliamentarians, research funders (CRUK, LR and DoH) with Geoff Thomas Foundation. There was a successful application to the Leukaemia and Lymphoma Research Clinical Trials Advisory Panel (http://www.lrf.org.uk/en/1/scirespan.html), with support from GTF to raise funding for national clinical trials group for early phase trials in blood cancers.</gtr:impact><gtr:outcomeId>4F63C5D0932</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type><gtr:url>http://www.geoffthomasfoundation.org/site/index.php</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>We are testing the clinical utility of this product</gtr:description><gtr:id>B3B95BC2-8E43-4320-8D92-AA7D52D7313D</gtr:id><gtr:impact>We have developed a new flow cytometric test of measurable residual disease in patients with Acute Myeloid Leukaemia.</gtr:impact><gtr:outcomeId>SNTZYzr59vV</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Detection of minimal residual disease in AML</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A multi-center, randomized, double-blind, placebo- controlled clinical trial of deferasirox in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload (TELESTO)

International Phase III trial of an oral iron chelator in Myelodsplastic Syndrome. Sponsored by Novartis. Vyas is UK CI.</gtr:description><gtr:id>AD85D9E4-D581-4629-9AA8-45F4A2C83317</gtr:id><gtr:impact>Impact awaited. Trial data closed and data being analysed.</gtr:impact><gtr:outcomeId>56d5d5b1426b82.74769642</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Novartis Telesto Trial</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>First-in-class Phase I trial of Humanized Monoclonal Antibody anti-CD47 in Acute Myeloid Leukemia. This is an academically funded, 7-year collaboration between my laboratory and Weissman Laboratory Stanford University. Sponsored by Stanford University. Oxford University is Sponsor in the EU. Oxford Oncology Clinical Trials Unit is running this multi-centre UK trial.

Trial will complete in 6/2017.

Phase II trials planned.</gtr:description><gtr:id>AE8EEC2D-A388-43D8-80AD-91B6D46F1BF2</gtr:id><gtr:impact>This first-in-class trial of a new monoclonal therapeutic antibody provides a rare example of academically funded work going from a laboratory observation through to development, manufacture and pre-clinical testing of a clinical therapuetic all the way to first clinical trial within the envelope of an entirely academically funded program.

This work is a collaboration between my laboratory, my clinical work in Oxford, the Oxford Clinical Oncology Early phase Trial Unit, the UK AML NCRI Clinical Trial Group and Stanford Unviersity. I am CI of the AML trial. The Stanford PI Dr Weissman has established a spin out company CD47 Inc to take this program further in clinical development.</gtr:impact><gtr:outcomeId>56d46b043f32d2.62059351</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Camellia trial</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A Phase 3, Multicenter, Randomized, Double-blind Study To Compare The Efficacy And Safety Of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care In Subjects With Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due To IPSS Lower-risk Myelodysplastic Syndromes. Vyas is UK national CI.</gtr:description><gtr:id>B4B16476-AE3A-49AD-A9F3-4CA61A2D53B1</gtr:id><gtr:impact>This Phase III licencing study will provide clincial dataset that could potential licence oral Azacitidine.</gtr:impact><gtr:outcomeId>56d5568805ef03.05348475</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Celgene MDS003</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>UK NCRI Group Phase III trial of therapy in children with AML. Vyas is lead on AML leukaemic stem cell studies.</gtr:description><gtr:id>BE56665A-4341-4FF5-890D-64557BC78AA3</gtr:id><gtr:impact>First UK Childhood AMl trial. Vyas is LSC lead</gtr:impact><gtr:outcomeId>56d555f75a0e81.84126205</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Myechild 01</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A Multi-center, Open-label, Phase I Study of Single Agent RO5045337 Administered Orally In patients with Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia (CML) In Blast Phase, Or Refractory Chronic Lymphocytic leukemia/Small Cell Lymphocytic Lymphoma (CLL/SCLL). 

Vyas was local PI.</gtr:description><gtr:id>9CC68EE7-DC48-4209-827E-7BAFA375F838</gtr:id><gtr:impact>Phase II trials started.</gtr:impact><gtr:outcomeId>56d5d72fef9be6.62617810</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Roche RO504337 in Acute Leukaemia</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>623870</gtr:ukcrnIsctnId><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>We have developed technology to monitor AML LSCs in all patients treated in UK AML NCRN (National Cancer Regional Network) Trials at diagnosis and following treatment.</gtr:description><gtr:id>78D73625-21E3-4CB1-AB84-09320941897C</gtr:id><gtr:impact>This technology has been transferred to the NHS.</gtr:impact><gtr:outcomeId>9E5149294A4</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Monitoring AML leukaemic stem cells</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>A Multicenter, Randomized, Open-Label, Parallel-Group, Phase 3 Trial Of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care For The Treatment of Myelodysplastic Syndromes (MDS). 

Vyas is local PI.</gtr:description><gtr:id>C025FD43-2E9A-4229-B7F6-69D9819C729E</gtr:id><gtr:impact>Led to licencing of Aza for MDS. NICE approved drug. Now standard of care for this patient group.</gtr:impact><gtr:outcomeId>56d5d5f60e2b13.75372260</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Celgene Aza-MDS-001:</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2008</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral A-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML)


Vyas is UK CI.</gtr:description><gtr:id>71710ABC-FF01-4765-AE27-DECCF19B1ED4</gtr:id><gtr:impact>Impact awaited.</gtr:impact><gtr:outcomeId>56d5d6fa606997.50080069</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>AG221 AML-005:</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Phase III UK AML trials: AML 19, LI1. Vyas is Lead for Genome England Program and flow cytometric leukaemic stem cell MRD studies.</gtr:description><gtr:id>D45B1AD9-B182-4558-9B9B-AE295AC0F0B8</gtr:id><gtr:impact>PV to write</gtr:impact><gtr:outcomeId>56d5564942bb58.57417433</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>UK AML NCRI Working Group AML 17, AML 18, AML 19 and LI1.</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>AML 17 - 55675535 , AML18 - 31682779 , AMl 19 78449203 , LI1 18218</gtr:ukcrnIsctnId><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Phase 3, Multicenter, Randomized, Open-label, Study Of Azacitidine Versus Conventional Care Regimens For The Treatment Of Older Subjects With Newly Diagnosed Acute Myeloid Leukaemia. 

Vyas was local PI.</gtr:description><gtr:id>61598B25-2096-45D8-A233-CEE53B8AA6BE</gtr:id><gtr:impact>Has led to EMA licence for Aza for AML. NICE refused to fund under TA. Celgene will put forward a patient access scheme for UK patients.</gtr:impact><gtr:outcomeId>56d5d635345789.43269027</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>Celgene Aza-AML-001:</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Phase II Randomised Trial of 5-Azacitidine versus 5- Azacitidine in combination with Vorinostat in patients with Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndromes Ineligible for Intensive Chemotherapy). 250 patients. Fully recruited. Vyas is co-Investigator and Scientific Lead.

Trial completed. Manuscript submitted.</gtr:description><gtr:id>356EDFCB-72AB-4E36-9BB4-EF5C1B7A7AC6</gtr:id><gtr:impact>This trial is helping to define azacitidine based combination therapies.</gtr:impact><gtr:outcomeId>56d55564301a84.76477516</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>RavVa trial:</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A Randomized, Multicenter, Open-label, Phase 2 Study Evaluating The Efficacy And Safety of Azacitidine Subcutaneous In Combination with Durvalumab (MEDIA4736) In Previously Untreated subjects With Higher-risk Myelodysplastic Syndromes (MDS) Or In Elderly (= 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible For Hematopoietic Stem Cell Transplantation (HSCT). Vyas is local PI.</gtr:description><gtr:id>DC32DA29-967D-4FAA-AA23-11596E1A20B0</gtr:id><gtr:impact>Impact awaited</gtr:impact><gtr:outcomeId>56d5d5747686f5.85501777</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Evaulation of anti-PD-L1 in high risk MDS and AML.</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG-221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATIO International Phase III trial of a first-in-class oral IDH2 inhibitor in Acute Myeloid Leukaemia. Sponsored by Celgene. Vyas is UK CI.</gtr:description><gtr:id>695E3585-E4B0-43E8-9131-C802DB8AF31E</gtr:id><gtr:impact>Impact still awaited.</gtr:impact><gtr:outcomeId>56d556e6dfc655.80450036</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>IDH2 inhibitor trial</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have developed secure web-based databases of clinical data associated with 439 bone marrow samples taken from patients with diseases affecting myeloid blood cells (Leukaemia and pre-leukaemia disorders). Clinical details are now automatically entered from collaborating NHS Trusts under approved protocols. The clinical data is linked to secure web-based databases containing detailed molecular, cellular and functional characterisation of stem and progenitor blood compartments from patient samples.</gtr:description><gtr:id>3ABABE87-8200-4CA7-B794-1934E5E65254</gtr:id><gtr:impact>This has allowed us to publish papers (PubMed IDs below) and secure the MRC Disease Team Award. PubMed IDs 19664981 19546437 19644143</gtr:impact><gtr:outcomeId>E6ECEF4F618</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Clinical and biological database of myeloid diseases</gtr:title><gtr:type>Biological samples</gtr:type><gtr:url>http://europepmc.org/abstract/MED/19664981</gtr:url><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>New antibodies to detect AML LSC</gtr:description><gtr:id>BF24F42E-AEC3-4C8F-841A-A6D04CBC2142</gtr:id><gtr:impact>Evaluation of the use of this research material is still in progress</gtr:impact><gtr:outcomeId>Z6mwhGtHpgB</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>New antibodies to detect AML LSC</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Collection of 3000 frozen viable cells patients with AML and Myelodysplasia (MDS) a preleukaemic form of AML.</gtr:description><gtr:id>B1B32EA5-F74A-4EDE-AF22-87D5D1AE1C73</gtr:id><gtr:impact>2 papers in NEJM and 3 paper in BLood 2 in Leukaemia</gtr:impact><gtr:outcomeId>B2eqkbAUeNZ</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Bone marrow cells</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have developed technology to monitor AML LSCs in all patients treated in UK AML NCRN (National Cancer Regional Network) Trials at diagnosis and following treatment.</gtr:description><gtr:id>5EC18E9D-CB56-48BE-86E1-A073CE81A76B</gtr:id><gtr:impact>This technology has been transferred to the NHS. For the first time, this study will determine if eradication cancer stem cells is required to cure cancer.</gtr:impact><gtr:outcomeId>54EB5C14992</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Fluorescence activated cell sort based protocol to monitor Acute Myeloid Leukaemia stem cells (LSCs).</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>A1E5B465-E629-411D-BC1C-F48F88C0A72B</gtr:id><gtr:title>Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de1abc4561036fa0e5e1f464b54dd8b7"><gtr:id>de1abc4561036fa0e5e1f464b54dd8b7</gtr:id><gtr:otherNames>Craddock CF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>5a609e6e245948.48173958</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7DD8FF89-426D-454E-BAD8-4ADD1B18DA62</gtr:id><gtr:title>Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a4de4f25ab06ec8486a5297e7e5328d"><gtr:id>3a4de4f25ab06ec8486a5297e7e5328d</gtr:id><gtr:otherNames>Goardon N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn><gtr:outcomeId>NXnc8v2fhRL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EAA549D2-6275-4860-8137-CE0E71244B71</gtr:id><gtr:title>Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ab8e8f7d43db2d02f8fbaf90a095239"><gtr:id>4ab8e8f7d43db2d02f8fbaf90a095239</gtr:id><gtr:otherNames>Giustacchini A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>5a609e1f3c7d99.44299737</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>652ACFE2-498C-4A96-86CE-13881704EBC6</gtr:id><gtr:title>GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b244db03523acfcca3e96a5f37df371"><gtr:id>8b244db03523acfcca3e96a5f37df371</gtr:id><gtr:otherNames>Roberts I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_15590_20_24021668</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBC19DA6-6E6F-4AE7-A093-FB09F6C08B55</gtr:id><gtr:title>Molecular targeting of cancer stem cells.</gtr:title><gtr:parentPublicationTitle>Cell stem cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fff9ad9ad870a670fe88aee2fe4bc105"><gtr:id>fff9ad9ad870a670fe88aee2fe4bc105</gtr:id><gtr:otherNames>Gupta R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1875-9777</gtr:issn><gtr:outcomeId>78DE704428A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE4B601F-42FA-4AFE-88B9-EA6399F689D3</gtr:id><gtr:title>Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c678f61d9baba78039fd689d1985a666"><gtr:id>c678f61d9baba78039fd689d1985a666</gtr:id><gtr:otherNames>Woll PS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn><gtr:outcomeId>5453ac697fd878.75247070</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED97E2C6-A623-4767-847F-4FC40E307722</gtr:id><gtr:title>Structural basis for LMO2-driven recruitment of the SCL:E47bHLH heterodimer to hematopoietic-specific transcriptional targets.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a017171bc87b2f6382042a9f9a3a08be"><gtr:id>a017171bc87b2f6382042a9f9a3a08be</gtr:id><gtr:otherNames>El Omari K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_15590_20_23831025</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>035F0032-650B-476F-9E0D-AE4C0BCB8CE8</gtr:id><gtr:title>Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70d30a423e81944842cc60515ff69f8c"><gtr:id>70d30a423e81944842cc60515ff69f8c</gtr:id><gtr:otherNames>Quek L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>585d379f003b40.39295341</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89D64AFC-2A3D-4260-97AD-C4D0C7DF7540</gtr:id><gtr:title>The impact of trisomy 21 on foetal haematopoiesis.</gtr:title><gtr:parentPublicationTitle>Blood cells, molecules &amp; diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b244db03523acfcca3e96a5f37df371"><gtr:id>8b244db03523acfcca3e96a5f37df371</gtr:id><gtr:otherNames>Roberts I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1079-9796</gtr:issn><gtr:outcomeId>pm_15590_20_23932236</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBD8D39F-0D1A-4EC6-A55D-483A67D82974</gtr:id><gtr:title>Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00223d0cb2f2c2b62ce0eb3ce2a48d21"><gtr:id>00223d0cb2f2c2b62ce0eb3ce2a48d21</gtr:id><gtr:otherNames>Craddock C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>pm_15590_20_23223186</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05F3C06F-57D2-4FD4-83C7-4037F9E3F730</gtr:id><gtr:title>The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9527bfcbdb625e348951bfb95a09345f"><gtr:id>9527bfcbdb625e348951bfb95a09345f</gtr:id><gtr:otherNames>Yip BH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>5a609dfd39b5b6.18693941</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>868E2B08-2278-40F9-BA32-01E52FF577E4</gtr:id><gtr:title>Clever leukemic stem cells branch out.</gtr:title><gtr:parentPublicationTitle>Cell stem cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c3545a0abfc060e990dc3441ab241c85"><gtr:id>c3545a0abfc060e990dc3441ab241c85</gtr:id><gtr:otherNames>Vyas P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1875-9777</gtr:issn><gtr:outcomeId>J1yJxqN6vL4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7745246C-2078-43E0-AC74-960B1B9121AD</gtr:id><gtr:title>Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d776866a5dee0d8e2f2f02303fedd07"><gtr:id>0d776866a5dee0d8e2f2f02303fedd07</gtr:id><gtr:otherNames>Eyre T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_15590_20_23175662</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>579518A1-26A4-4B31-9D70-AFF2EADD9E2F</gtr:id><gtr:title>Assessment of minimal residual disease in acute myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Current opinion in oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa63804623afefe42d3849f6aead48b0"><gtr:id>fa63804623afefe42d3849f6aead48b0</gtr:id><gtr:otherNames>Grimwade D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1040-8746</gtr:issn><gtr:outcomeId>Xu1FpEEHAbW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F329465-46BF-46D3-BB83-BAEAD5B42E48</gtr:id><gtr:title>Assessment of Minimal Residual Disease in Standard-Risk AML.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7157bdaf7078a36d0c29de1f4ee8f0fc"><gtr:id>7157bdaf7078a36d0c29de1f4ee8f0fc</gtr:id><gtr:otherNames>Ivey A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>56cc13a50e3875.21731321</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3F5DE0F-5AA9-4770-B5CA-539C6FD8E952</gtr:id><gtr:title>Clinical and biological implications of driver mutations in myelodysplastic syndromes.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4c954d767ba92727eabc85d0b700988"><gtr:id>c4c954d767ba92727eabc85d0b700988</gtr:id><gtr:otherNames>Papaemmanuil E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_15590_20_24030381</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E3907F0-BC74-4E9B-A038-0FADA0EE3A4A</gtr:id><gtr:title>The impact of trisomy 21 on early human hematopoiesis.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4f5d0920d73a0a7caca3b42bf26d5a4"><gtr:id>f4f5d0920d73a0a7caca3b42bf26d5a4</gtr:id><gtr:otherNames>Roy A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>pm_15590_20_23343767</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F0C8621-0316-470A-BE82-E9C581E2C2C5</gtr:id><gtr:title>Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc665401f5b0d46333c809dc8a502fb1"><gtr:id>fc665401f5b0d46333c809dc8a502fb1</gtr:id><gtr:otherNames>Amatangelo MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5a609e3d9eccb1.20262709</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18DE3340-9881-4DDE-8B1C-8AA3A7937043</gtr:id><gtr:title>Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de95b72cde69d3a1a807171fad58b602"><gtr:id>de95b72cde69d3a1a807171fad58b602</gtr:id><gtr:otherNames>Jan M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>pm_15590_20_22932223</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>321E6899-7190-4EDE-8E63-4BC6235CE507</gtr:id><gtr:title>Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e0b20cfc0518dfe2421077726527510"><gtr:id>8e0b20cfc0518dfe2421077726527510</gtr:id><gtr:otherNames>Karamitros D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>5a609e858339b8.50318694</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64F02AA5-74B7-4A5F-9C50-219C10860097</gtr:id><gtr:title>Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a4de4f25ab06ec8486a5297e7e5328d"><gtr:id>3a4de4f25ab06ec8486a5297e7e5328d</gtr:id><gtr:otherNames>Goardon N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>E410953F0D4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4AF1813-8B50-4C3C-9B5C-D758B44568F1</gtr:id><gtr:title>FLT3-ITDs instruct a myeloid differentiation and transformation bias in lymphomyeloid multipotent progenitors.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fb12a98d4056670ebefede87ebda6ba"><gtr:id>5fb12a98d4056670ebefede87ebda6ba</gtr:id><gtr:otherNames>Mead AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_15590_20_23727242</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>492DD38F-7E8E-4AB8-B528-6F3813D570AF</gtr:id><gtr:title>Enasidenib in mutantrelapsed or refractory acute myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfbb54f62d263d00cd911b08033c95e2"><gtr:id>cfbb54f62d263d00cd911b08033c95e2</gtr:id><gtr:otherNames>Stein EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5a609e56b22214.51272307</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77CCAFE4-FDA6-47DF-B7DC-9BC1ED7C2673</gtr:id><gtr:title>An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 low blasts.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4565dafaf87d213d5e13e790513349db"><gtr:id>4565dafaf87d213d5e13e790513349db</gtr:id><gtr:otherNames>Khan N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>56bddf3992bb41.31775809</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A8778DD-403D-4D7B-A12E-5612D3392BF0</gtr:id><gtr:title>Uncoupling VEGFA functions in arteriogenesis and hematopoietic stem cell specification.</gtr:title><gtr:parentPublicationTitle>Developmental cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e3074d3fc43b0c44b68d9cfe2dfd095"><gtr:id>1e3074d3fc43b0c44b68d9cfe2dfd095</gtr:id><gtr:otherNames>Leung A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1534-5807</gtr:issn><gtr:outcomeId>pm_15590_20_23318133</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CCFC9D67-8D35-4B40-A143-849AAFB5371D</gtr:id><gtr:title>Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5eb6709aee32b4deee2432c393eec70"><gtr:id>c5eb6709aee32b4deee2432c393eec70</gtr:id><gtr:otherNames>Schuurhuis GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5a93d1b70879c6.87730594</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6DADE9F-8B6C-4660-992E-3260FADF172B</gtr:id><gtr:title>Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9fe1d78d9f73909aa0285fb1be6f87e2"><gtr:id>9fe1d78d9f73909aa0285fb1be6f87e2</gtr:id><gtr:otherNames>Mussai F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_15590_20_23733335</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FEE313DE-4707-4436-9E3E-C02B636A87F3</gtr:id><gtr:title>Persistent malignant stem cells in del(5q) myelodysplasia in remission.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a96d892dd559c3e7d3575f4ae7396778"><gtr:id>a96d892dd559c3e7d3575f4ae7396778</gtr:id><gtr:otherNames>Tehranchi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>SW3AQLMqaZL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>440440FB-518B-48BD-BFE2-7F78762C55E5</gtr:id><gtr:title>Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1f600d0e0aba139a753876d3f33a5b58"><gtr:id>1f600d0e0aba139a753876d3f33a5b58</gtr:id><gtr:otherNames>van de Loosdrecht AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>CC995553571</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BFD00C59-6B45-4A7F-9D21-12168898ED4D</gtr:id><gtr:title>Impact of isolated germline JAK2V617I mutation on human hematopoiesis.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fb12a98d4056670ebefede87ebda6ba"><gtr:id>5fb12a98d4056670ebefede87ebda6ba</gtr:id><gtr:otherNames>Mead AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_15590_20_23535062</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>787B86A3-BF75-4B27-B180-0E991C4701B4</gtr:id><gtr:title>Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21cab1a100cc994e6c9417780528fdde"><gtr:id>21cab1a100cc994e6c9417780528fdde</gtr:id><gtr:otherNames>Ju YS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn><gtr:outcomeId>545fcb3f4b1768.97576070</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C817861-95B8-42E4-A1E5-8539A2528E5F</gtr:id><gtr:title>Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4c954d767ba92727eabc85d0b700988"><gtr:id>c4c954d767ba92727eabc85d0b700988</gtr:id><gtr:otherNames>Papaemmanuil E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>mTfVJ5NeyPc</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1000729</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>